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Abstract
Intraerythrocytic Plasmodium produces large amounts of toxic heme during the digestion of hemoglobin, a parasite speciWc pathway.
Heme is then partially biocristallized into hemozoin and mostly detoxiWed by reduced glutathione. We proposed an in vitro micro assay to
test the ability of drugs to inhibit heme-glutathione dependent degradation. As glutathione and o-phthalaldehyde form a Xuorescent
adduct, we followed the extinction of the Xuorescent signal when heme was added with or without antimalarial compounds. In this assay,
50 M of amodiaquine, arthemether, chloroquine, methylene blue, meXoquine and quinine inhibited the interaction between glutathione
(50 M) and heme (50 M), while atovaquone did not. Consequently, this test could detect drugs that can inhibit heme–GSH degradation
in a fast, simple and speciWc way, making it suitable for high throughput screening of potential antimalarials.
Index Descriptors and Abbreviations: Plasmodium falciparum; Glutathione; Heme; Antimalarials; Screening; GSH, Reduced glutathione; OPA, o-phthal-
aldehyde; HPLC, high performance liquid chromatography; AMO, amodiaquine; ART, arthemether; ATO, atovaquone; CQ, chloroquine; MB, methy-
lene blue; MEF, meXoquine; Q, quinine1. Introduction
Drug-resistant parasites and insecticide-resistant mos-
quito vectors have made treatment and control of malaria
more diYcult. Therefore safe, aVordable, and eVective new
drugs are urgently needed (WHO-TDR The World Health
Organization, 2006). The search for new antimalarials is
generally based on in vitro tests against cultivated Plasmo-
dium falciparum and/or in vivo against rodent malaria mod-
els. Apart from being expensive and raising ethical issues,
these tests are also time-consuming, results being obtained
in 3–5 days, which is not suitable for high throughput
screening. A faster and cheaper way to detect antimalarial
activities is to study the impact of a drug on a Plasmodium
* Corresponding author. Fax: +33 05 62 19 39 01.
E-mail address: ericdeharo@yahoo.fr (E. Deharo).speciWc metabolic event or a “target”, reproduced in micro-
titerplates. An improved understanding of the biochemistry
of malaria parasites has made it possible to identify many
potential targets for new drugs, the degradation of hemo-
globin being one of them. The malaria parasite breaks up
hemoglobin inside the red blood cells, as a major source of
production of amino acids, releasing free toxic heme. Plas-
modium protects itself against the toxicity of heme by bio-
cristallizing around 30% of it into insoluble hemozoïne.
Many tests to detect potential antimalarials were based on
this pathway (Baelmans et al., 2000; Basilico et al., 1998;
Deharo et al., 2002; Kurosawa et al., 2000). Interestingly,
the major degradation pathway of heme is not the biocris-
tallization, since around 70% of non-crystallized heme exits
the food vacuole and is subsequently catabolized by GSH,
leading to the formation of oxidized glutathione (Ginsburg
et al., 1998). Consequently a drug that can inhibit the inter-
action between GSH and heme should have even better
potential antimalarial properties than one that acts on bio-
cristallization. Previous studies (Cohn and Lyle, 1966; His-
sin and Hilf, 1976) have shown that GSH reacted with OPA
in a highly speciWc manner, giving a strong Xuorescent
GSH–OPA adduct with excitation/emission spectra reach-
ing 350 and 420 nm, respectively (Neuschwander-Tetri and
Roll, 1989; Hissin and Hilf, 1976). On this basis we devel-
oped a new in vitro assay to follow heme–GSH dependent
degradation by Xuorescence spectroscopy. For this purpose
we Wrst determined the optimal conditions of the test by
HPLC, and we subsequently measured the activity of
AMO, ART, ATO, CQ, MB, MEF, and Q in this model.
2. Materials and methods
2.1. Chemicals
All chemicals were from Sigma–Aldrich (L’Isle d’Abeau
Chesnes, France) except: acetonitrile (HPLC grade) from
SDS (Peypin, France), ART from Cambrex (Verviers, Bel-
gium), ATO was a gift of GlaxoSmithKline (Marly-le-Roi,
France) and MEF from HoVmann-La Roche (Basel, Swit-
zerland).
GSH (Sigma–Aldrich G4251) is manufactured by
extraction from yeast and does not contain materials of
animal origin.
2.2. HPLC study for the assessing of optimal conditions
The OPA–GSH adduct detection was optimized by
HPLC according to Cereser et al. (2001). A Waters HPLC
system was used (Waters 600 solvent delivery system,
Waters 717 plus auto sampler and Waters 474 scanning
Xuorescence detector). Analysis were monitored with
ex D 320 nm and em D 450 nm (Hissin and Hilf, 1976; Scad-
uto, 1988). Data were acquired and processed in a Waters
Millenium workstation. An Inertsil, ODS-2, C18 column
(5m, 250 £ 4.6 mm) (AIT, Mesnil Le Roi, France) was
used to separate the GSH, OPA, and OPA–GSH adduct.
Column temperature was kept at 37 °C. The mobile phase
(isocratic mode) was a mixture of solvents 35% and 65%
CH3CN/sodium acetate buVer, 50 mM, pH D 6.2, respec-
tively. The Xow rate was 0.7 ml/min and 20l of sample
were injected. After the optimization of the OPA–GSH
adduct detection by liquid chromatography, the heme–
GSH interaction was also studied (same experimental con-
ditions). The main experimental parameters of both studied
reactions (GSH derivation and heme–GSH interaction)
were: incubation temperature, atmosphere (O2, N2), pH,
OPA/GSH, and heme/GSH ratio values.
2.3. Heme-glutathione interaction study
The OPA–GSH Xuorescent adduct was detected with a
96-well plate reader (BGM, Polarstar) at 37°C in 0.2 M
Hepes buVer, pHD7. Standard solutions of GSH (300M)
in HCl (0.1M), OPA (17.5mM) in a mixture of methanol/sodium tetraborate and of heme (300M) in NaOH (0 2 M)
were freshly prepared. Drugs, 10 mM in MeOH or in
Hepes buVer (pHD7), were diluted with HEPES buVer
to 300M. These solutions were kept in darkness. Final con-
centrations in the plate were 50M except for OPA, whose
concentration was 2.5 mM. Drugs (25l) were incubated with
GSH (25l) and heme (25l) for 30 min and Xuorescence
intensities measured at tD 0 and at tD30min. Fluorescence
emission started with the addition of 25l of OPA
(17.5 mM). Plates were shaken for 10 s with a shaking width
of 1 mm. OPA was added just before the Xuorescence
measurement at 0 and 30 min incubation times. The follow-
ing mixtures were used as control to determine potential
interactions resulting into a Xuorescence emission: drug/
GSH (50M/50M), drug/heme (50M/50M), drug/OPA
(50M/2.5 mM), heme/OPA (50M/2.5 mM), GSH/OPA
(50M/2.5 mM) and HEPES buVer/OPA (0.2 M/2.5 mM).
Fluorescence reduction obtained with heme–GSH between
tD0 and tD30min was the “positive” control. Results
were expressed in the average % of GSH after a 30 min incu-
bation in the media. The Xuorescence intensity at tD0min
corresponds to 100% of GSH. The % of remaining GSH was
deWned as (Fluorescence(tD30min)/Fluorescence (tD0 min) £100).
A statistical analysis was performed with the STATA 7.0
software. A Student’s t-test was used to compare the % GSH
remaining values.
3. Results and discussion
We Wrst assessed the best experimental conditions to
carry out the assay, starting from experimental data
reported by Ginsburg (Ginsburg et al., 1998). The HPLC
study of GSH derivation by OPA indicated a GSH/OPA
optimal ratio of 1/50 and an OPA derivation time of 5 min.
As shown in Table 1, the following conditions were also
established: GSH/heme: 1/1; drug/GSH/heme: 1/1/1 and
incubation time: 30 min. Since under nitrogen the heme–
GSH dependent degradation was inhibited, assays were
carried out in a normally oxygenated environment, at
37 °C.
As shown in Fig. 1, the percentage of remaining GSH
after 30 min of incubation of GSH + heme with AMO,
ART, CQ, MB, MEF, and Q was signiWcantly higher than
the positive control (GSH + heme + solvent), AMO being
the most active. This is in line with the fact that AMO, CQ,
and MEF are known to competitively inhibit the degradation
Table 1
Optimum conditions to perform the test
GSH/OPA optimal ratio 1/50
OPA derivation time 5 min
GSH/heme optimal ratio 1/1
Drug/GSH/heme optimal ratio 1/1/1
Incubation time 30 min
Atmosphere Room
Temperature 37 °C
pH 7
of heme by GSH (Ginsburg et al., 1998). It is also known
that MB links itself to heme and inhibits -hematin forma-
tion much more eVectively than Q, which is the least active
drug in our test (Deharo et al., 2002; Wainwright and Ama-
ral, 2005). Interestingly, in our ferriprotoporphyrin IX bio-
mineralization inhibition test (Deharo et al., 2002) Q was
more than 10 times less active than CQ and MB, while in
the present study the diVerence was not so obvious. This
means that Q is more active on the heme–GSH interaction
than on the hemozoin formation. In a previous study based
on scanning spectrophotometry of heme–GSH interaction
at 360 nm, Steele et al. (2002) also showed the inhibitory
eVect of AMO, CQ, and Q but claimed that ART was inac-
tive. This sounds strange because even if ART has been
recently shown to target the sarco/endoplasmic reticulum
calcium-dependent ATPase of Plasmodium (Eckstein-Lud-
wig et al., 2003), free radicals generated from ART are
known to form adducts with a variety of biological macro-
molecules, including heme (Meshnick, 2002), which is in
line with our results. On the contrary ATO did not interfere
with the heme–GSH interaction, the remaining GSH being
similar to control. This was expected as ATO does not act
on heme detoxiWcation pathways but on the electron trans-
port through the parasite mitochondrial cytochrome bc1
complex and aVects the mitochondrial membrane potential
(Mather et al., 2005). These results prove the capacity of the
assay to diVerentiate compounds that do not act on the
heme–GSH dependent degradation pathway.
In conclusion, the technique reported herein is simple,
fast and speciWc to detect molecules that can inhibit heme–
GSH dependent degradation.
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